Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Oct. 31, 2017
Oct. 31, 2016
Revenues:    
Clinical laboratory services $ 20,334 $ 18,558
Product revenues 7,081 7,426
Royalty and license fee income 261 300
Total revenues 27,676 26,284
Operating costs, expenses:    
Cost of clinical laboratory services 12,042 10,896
Cost of product revenues 3,389 3,309
Research and development 747 822
Selling, general, and administrative 10,891 11,494
Provision for uncollectible accounts receivable 814 669
Legal fee expense 431 372
Total operating costs, expenses 28,314 27,562
Operating loss (638) (1,278)
Other income (expense):    
Interest 157 46
Other 36 119
Foreign exchange loss (195) (361)
Loss before income taxes (640) (1,474)
Provision for income taxes
Net loss $ (640) $ (1,474)
Net loss per common share:    
Basic (in Dollars per share) $ (0.01) $ (0.03)
Diluted (in Dollars per share) $ (0.01) $ (0.03)
Weighted average common shares outstanding:    
Basic (in Shares) 46,914 46,272
Diluted (in Shares) 46,914 46,272